MP66-13 XENON FACILITATES SCHWANN CELL DEMYELINATION VIA INHIBITION OF SPRY2 IN TREATING ERECTILE DYSFUNCTION AFTER CAVERNOUS NERVE INJURY

Baibing Yang,Xiaozhi Zhao,Run Wang,Yutian Dai
DOI: https://doi.org/10.1097/01.ju.0001009468.01097.19.13
2024-01-01
Abstract:You have accessJournal of UrologySexual Function/Dysfunction: Basic Research & Pathophysiology (MP66)1 May 2024MP66-13 XENON FACILITATES SCHWANN CELL DEMYELINATION VIA INHIBITION OF SPRY2 IN TREATING ERECTILE DYSFUNCTION AFTER CAVERNOUS NERVE INJURY Baibing Yang, Xiaozhi Zhao, Run Wang, and Yutian Dai Baibing YangBaibing Yang , Xiaozhi ZhaoXiaozhi Zhao , Run WangRun Wang , and Yutian DaiYutian Dai View All Author Informationhttps://doi.org/10.1097/01.JU.0001009468.01097.19.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cavernous nerve injury induced erectile dysfunction (ED) is the most common complication after radical prostatectomy for prostate cancer. Our previous studies found that xenon (Xe) can partially restore the erectile function and cavernous nerve function of rats with neurogenic ED, but the mechanism is unclear. Schwann cells (SC) play an important role in peripheral nerve repair, and after axonal injury, SC undergo demyelination and transform into repair-type SC to promote repair. The purpose of this study is to verify whether Xe promotes the demyelination of Schwann cells and its molecular mechanism. METHODS: Human SCs were cultured in vitro and given Echo-lipid particles (ELIPs) carrying Xe. The control group was given empty ELIPs. Ultrasound was performed above the culture dish to break ELIPs and release the gas. After treatment, the expression level of the EGR2 gene, a marker of SC demyelination, was detected, and RNA was extracted for mRNA sequencing. Sequencing results were validated in SC and rat dorsal root ganglion (MRP) tissues through Western blot and qPCR. RESULTS: After Xe treatment, the level of EGR2 in SC cultured in vitro decreased, indicating that Xe treatment can promote the demyelination process of SC. RNA-sequencing results showed that after Xe treatment, 88 genes were up-regulated and 231 genes were down-regulated. Top 10 KEGG pathway enrichment analysis suggested an increase in MAPK pathway expression. Meanwhile, among the differentially expressed genes, we found that the expression of SPRY2 (Sprouty RTK Signaling Antagonist 2) decreased, a negative feedback regulator of the MAPK pathway. Using qPCR and Western blot on SC and rat MPG tissues in vitro, we validated the sequencing results and found that after Xe treatment, the expression level of SPRY2 decreased, and the level of pERK increased. CONCLUSIONS: Xe may promote the demyelination of Schwann cells and the repair of cavernous nerves by inhibiting the SPRY2 level of SC, reducing its inhibition of the MAPK/ERK pathway. Download PPTDownload PPT Source of Funding: The National Natural Science Foundation of China (Grant No. 82301822) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1090 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Baibing Yang More articles by this author Xiaozhi Zhao More articles by this author Run Wang More articles by this author Yutian Dai More articles by this author Expand All Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?